Literature DB >> 18548349

Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.

Mehran Howaizi1, Pierre Akue-Goeh, Françoise Maurer-Chagrin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18548349     DOI： 10.1007/s10620-008-0341-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  12 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 2.  Management of cirrhosis due to chronic hepatitis C.

Authors:  Gregory T Everson
Journal:  J Hepatol       Date:  2005       Impact factor: 25.083

3.  Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

Authors:  Jean-Pierre Bronowicki; Denis Ouzan; Tarik Asselah; Hervé Desmorat; Jean-Pierre Zarski; Juliette Foucher; Marc Bourlière; Christophe Renou; Albert Tran; Pascal Melin; Christophe Hézode; Michelle Chevalier; Magali Bouvier-Alias; Stéphane Chevaliez; François Montestruc; Isabelle Lonjon-Domanec; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2006-07-24       Impact factor: 22.682

4.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

Authors:  Alessandra Mangia; Rosanna Santoro; Nicola Minerva; Giovanni L Ricci; Vito Carretta; Marcello Persico; Francesco Vinelli; Gaetano Scotto; Donato Bacca; Mauro Annese; Mario Romano; Franco Zechini; Fernando Sogari; Fulvio Spirito; Angelo Andriulli
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

5.  A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.

Authors:  Jeffrey S Crippin; Tim McCashland; Norah Terrault; Patricia Sheiner; Michael R Charlton
Journal:  Liver Transpl       Date:  2002-04       Impact factor: 5.799

6.  Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

Authors:  Angelo Iacobellis; Massimo Siciliano; Francesco Perri; Brigida E Annicchiarico; Gioacchino Leandro; Nazario Caruso; Laura Accadia; Giuseppe Bombardieri; Angelo Andriulli
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

Review 7.  Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials.

Authors:  Jesper Brok; Lise L Gluud; Christian Gluud
Journal:  Am J Gastroenterol       Date:  2006-02-22       Impact factor: 10.864

Review 8.  Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.

Authors:  Robert J Fontana; Gregory T Everson; Sony Tuteja; Hugo E Vargas; Mitchell L Shiffman
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

9.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Authors:  Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

10.  Antiviral action of ribavirin in chronic hepatitis C.

Authors:  Jean-Michel Pawlotsky; Harel Dahari; Avidan U Neumann; Christophe Hezode; Georgios Germanidis; Isabelle Lonjon; Laurent Castera; Daniel Dhumeaux
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.